| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.59(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.29 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
775,593 |
1,203,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,587,745 |
$9,406,570 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
36 |
60 |
105 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosenbaum David P. |
Chief Development Officer |
• – – |
2017-08-07 |
4 |
A |
$0.00 |
$0 |
D/D |
26,512 |
66,641 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2017-08-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,884 |
38,894 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2017-08-07 |
4 |
A |
$0.00 |
$0 |
D/D |
26,512 |
48,588 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2017-08-07 |
4 |
A |
$0.00 |
$0 |
D/D |
79,535 |
99,038 |
|
- |
|
| Seeto Reginald |
Chief Operating Officer |
• – – |
2017-08-07 |
4 |
A |
$0.00 |
$0 |
D/D |
26,512 |
158,133 |
|
- |
|
| Mott David M |
Director |
– • • |
2017-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,534 |
33,877 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2017-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,697 |
26,993 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2017-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
11,627 |
21,481 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2017-04-18 |
4 |
S |
$11.98 |
$24,577 |
D/D |
(2,051) |
40,129 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2017-03-10 |
4 |
S |
$13.48 |
$13,482 |
I/I |
(1,000) |
1,277 |
|
- |
|
| Caldwell Jeremy S |
EVP, Chief Scientific Officer |
• – – |
2017-03-03 |
4 |
S |
$14.14 |
$14,512 |
D/D |
(1,026) |
17,985 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2017-03-01 |
4 |
AS |
$13.70 |
$41,100 |
D/D |
(3,000) |
68,450 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2017-03-01 |
4 |
OE |
$0.54 |
$1,620 |
D/D |
3,000 |
71,450 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2017-02-01 |
4 |
AS |
$12.00 |
$36,000 |
D/D |
(3,000) |
67,510 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2017-02-01 |
4 |
OE |
$0.54 |
$1,620 |
D/D |
3,000 |
70,510 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
67,510 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
40,129 |
|
- |
|
| Seeto Reginald |
Chief Operating Officer |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
131,621 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
21,585 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
19,503 |
|
- |
|
| Caldwell Jeremy S |
EVP, Chief Scientific Officer |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
17,985 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
17,985 |
|
- |
|
| Korner Paul |
EVP, Chief Medical Officer |
• – – |
2017-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,985 |
72,608 |
|
- |
|
| Korner Paul |
EVP, Chief Medical Officer |
• – – |
2017-01-05 |
4 |
S |
$12.95 |
$79,384 |
D/D |
(6,130) |
54,623 |
|
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2016-12-16 |
4 |
S |
$14.48 |
$13,035 |
I/I |
(900) |
636 |
|
- |
|
540 Records found
|
|
Page 15 of 22 |
|
|
0.08 (1.18%) 
